IOBTQ.US IO Biotech, Inc.
- Market cap
- USD 7.19K
- P/E
- -
- P/B
- 0.01x
- ROE
- -8,344.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.
Is IOBTQ.US undervalued?
Graham numberThe Graham number of IO Biotech, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IO Biotech, Inc. fundamental analysis
No fundamental analysis for IO Biotech, Inc. yet.
IO Biotech, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase…
Full company profileIO Biotech, Inc. financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
IO Biotech, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -41.2M | -71.4M | -91.4M | -95.2M | -86.8M |
| EBITDA | -67.4M | -69.3M | -90.7M | -94.3M | -75.9M |
| Net Income | -67.9M | -71.5M | -86.1M | -95.5M | -76.0M |
| EPS | -2.36 | -2.48 | -1.31 | -1.45 | -1.09 |
| Balance Sheet | |||||
| Total Assets | 222M | 152M | 151M | 67.7M | 40.0M |
| Total Liabilities | 10.4M | 13.0M | 17.6M | 20.7M | 39.0M |
| Shareholders' Equity | 212M | 139M | 133M | 47.0M | 911K |
| Cash & Short-term Investments | 212M | 143M | 143M | 60.0M | 30.7M |
| Cash Flow | |||||
| Operating Cash Flow | -40.6M | -59.7M | -71.7M | -82.3M | -81.8M |
| Capital Expenditure | 153K | 690K | 323K | 44.0K | 77.3K |
| Free Cash Flow | -40.8M | -60.4M | -72.1M | -82.4M | -81.9M |
| Ratios | |||||
| ROE | -32.0% | -51.5% | -64.6% | -203.1% | -8,344.8% |
| ROA | -30.5% | -47.1% | -57.1% | -141.1% | -190.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
IO Biotech, Inc. dividends
IO Biotech, Inc. has not paid dividends in the last 4 fiscal years.
Who owns IO Biotech, Inc.
- Insiders 0.29%
- Institutions 30.06%
- Public & others 69.65%
- Shares outstanding 71.9M
- Free float 53.6M
IO Biotech, Inc. company profile
- Company name
- IO Biotech, Inc.
- Ticker
- IOBTQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 80
- Fiscal year end
- December
- Address
- Ole MaalOees Vej 3, Copenhagen, Denmark, 2200
- Phone
- 45 70 70 29 80
- Website
- iobiotech.com
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark. On March 31, 2026, IO Biotech, Inc., along with its affiliate, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.